What additional benefits does adding finerenone offer when combined with sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with midrange ejection fraction (HFmrEF) and ...

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients ...

No randomized controlled trial has yet demonstrated a statistically significant reduction in mortality in HFmrEF or HFpEF ...

The findings, he added, support current guidelines that encourage physicians to “leverage” episodes of worsening heart failure, and heart failure hospitalizations in particular, as a good time to ...

However, their efficacy in HFmrEF or HFpEF remains uncertain. The TOPCAT trial (treatment of preserved cardiac function heart ...

USA: The FINEARTS-HF trial revealed that the benefit-risk profile of finerenone (Kerendia) for heart failure with mildly ...

A major trend in the HF treatment landscape is that many companies ... "ESC 2024: FINEARTS-HF trial sheds positive light on Kerendia for HFmrEF/HFpEF" was originally created and published by ...